Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
TD Cowen Reiterates Buy Rating on Legend Biotech Corp. (LEGN), PT $62, 'We Like The Profile At These Levels'
May 13, 2025 4:38 PM EDTTD Cowen analyst Yaron Werber reiterated a Buy rating and $62.00 price target on Legend Biotech Corp. (NASDAQ: LEGN).
The analyst comments "Our Take: Carvykti Continues Solid Ramp, With Growth Likely Weighted Towards H2:25 We Like The Profile At These Levels We like the risk/reward of the stock at these levels given a solid sales ramp for Carvykti on the heels of strong demand, especially in... More
